Patent · US Expired

Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof

US6060257A · kind A · utility

1Cited by

1References

9Claims

0Family size

Assignee

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

Jean Herman · Brussels, BE
Pierre Coulie · Brussels, BE
Thierry Boon-Falleur · Brussels, BE
Pierre van der Bruggen · Brussels, BE
Immanuel F. Luescher · Épalinges, CH

Key dates

Filing date	Feb 20, 1996
Grant date	May 9, 2000
Priority date	—
Expiry date	Feb 20, 2016

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/136
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Tumor rejection antigens presented by HLA-244 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.